Gastrointestinal lymphoma: prevention and treatment of early lesions

Best Pract Res Clin Gastroenterol. 2001 Apr;15(2):337-54. doi: 10.1053/bega.2000.0177.


Gastrointestinal lymphomas comprise a group of distinct clinicopathological entities. Differences in lifestyle and environmental factors between countries could account for the variety in the distribution of the main subtypes: low-grade B-cell lymphomas of the mucosa-associated lymphoid tissue type, alpha-chain disease and enteropathy (coeliac disease)-associated T-cell lymphoma (EATL). The possibility of preventing these lymphomas implies a knowledge of their natural history together with an identification of potential predisposing factors. The development of the lymphoid hyperplasia and subsequently low-grade lymphoma with the possibility of high-grade transformation is a multifactorial process involving both antigenic and host-related factors. The pathogenic role of Helicobacter pylori and gluten has been demonstrated in gastric lymphoma and enteropathy-associated T-cell lymphoma respectively, while environmental factors, especially non-specific bacterial ones, may play a major role in the pathogenesis of alpha-chain disease. The most difficult task in preventing these lymphomas is the recognition of early lesions likely to regress after the removal of the exogenous stimulus.

Publication types

  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Combined Modality Therapy
  • Female
  • Gastrointestinal Neoplasms / complications
  • Gastrointestinal Neoplasms / diagnosis*
  • Gastrointestinal Neoplasms / mortality
  • Gastrointestinal Neoplasms / prevention & control*
  • Humans
  • Lymphoma, B-Cell, Marginal Zone / complications
  • Lymphoma, B-Cell, Marginal Zone / diagnosis*
  • Lymphoma, B-Cell, Marginal Zone / mortality
  • Lymphoma, B-Cell, Marginal Zone / prevention & control*
  • Lymphoma, Non-Hodgkin / complications
  • Lymphoma, Non-Hodgkin / diagnosis*
  • Lymphoma, Non-Hodgkin / mortality
  • Lymphoma, Non-Hodgkin / prevention & control*
  • Male
  • Mass Screening / methods
  • Precancerous Conditions / diagnosis*
  • Prognosis
  • Severity of Illness Index
  • Survival Rate
  • Treatment Outcome